Remote Monitoring and Data Collection for Decentralized Clinical Trials.

ABSTRACT:

Importance

Less than 5% of patients with cancer enroll in a clinical trial, partly due to financial and logistic burdens, especially among underserved populations. The COVID-19 pandemic marked a substantial shift in the adoption of decentralized trial operations by pharmaceutical companies.

Objective

To assess the current global state of adoption of decentralized trial technologies, understand factors that may be driving or preventing adoption, and highlight aspirations and direction for industry to enable more patient-centric trials.

Design, setting, and participants

The Bloomberg New Economy International Cancer Coalition, composed of patient advocacy, industry, government regulator, and academic medical center representatives, developed a survey directed to global

SUBMITTER: Daly B 

PROVIDER: S-EPMC11015350 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature